Getting Real with Biotech Valuation

Описание к видео Getting Real with Biotech Valuation

This webinar provides insight into unique methods employed when valuing products and  companies in biotech. For example: How is a DCF model different for these high growth drug R&D companies? What are Real Options and when should they be used? If you have a background in finance, are new to the world of biotech valuation, or are new to the Real Options approach to valuation, then this webinar is for you.

These distinguished speakers were featured on the panel:
-Vladimir Antikarov, Verea Group LLC, Principal
-Patrik Frei, Venture Valuation, CEO
-David Thomas, BIO, Director of Industry Research & Policy Analysis (Moderator)

Комментарии

Информация по комментариям в разработке

Похожие видео